KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $3.0 billion.

  • Pfizer's Accumulated Expenses fell 1025.72% to $3.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 billion, marking a year-over-year decrease of 1025.72%. This contributed to the annual value of $3.8 billion for FY2024, which is 3825.65% up from last year.
  • According to the latest figures from Q3 2025, Pfizer's Accumulated Expenses is $3.0 billion, which was down 1025.72% from $2.4 billion recorded in Q2 2025.
  • Pfizer's 5-year Accumulated Expenses high stood at $3.8 billion for Q4 2024, and its period low was $2.0 billion during Q3 2023.
  • Moreover, its 5-year median value for Accumulated Expenses was $2.6 billion (2024), whereas its average is $2.6 billion.
  • Per our database at Business Quant, Pfizer's Accumulated Expenses plummeted by 1852.07% in 2023 and then surged by 4262.23% in 2024.
  • Over the past 5 years, Pfizer's Accumulated Expenses (Quarter) stood at $3.3 billion in 2021, then increased by 2.25% to $3.4 billion in 2022, then fell by 18.52% to $2.8 billion in 2023, then surged by 38.26% to $3.8 billion in 2024, then fell by 20.9% to $3.0 billion in 2025.
  • Its Accumulated Expenses stands at $3.0 billion for Q3 2025, versus $2.4 billion for Q2 2025 and $2.6 billion for Q1 2025.